Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Exclusion Criteria

• •Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 5 days of dosing
• •Use of any investigational agent or study treatment within 30 days of dosing
• •Use of any protein or antibody-based therapeutic agents within 3 months of Screening
• •Prior exposure to LX4211
• •Use of cigarettes or any tobacco products within 2 months prior to Screening and while participating in the study
• •History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption
• •History of any major surgery within 6 months of Screening
• •History of any hypersensitivity to the inactive components of LX4211
• •History of renal disease or significantly abnormal kidney function tests
• •History of hepatic disease or significantly abnormal liver function tests
• •History of any active infection within 14 days prior to Day 1
• •History of alcohol or substance abuse within 2 years prior to Day 1
• •Donation or loss of \>400 mL of blood or blood product within 3 months of dosing
• •Positive urine glucose at Screening
• •Positive urine screen for drugs of abuse, or urine test for alcohol at Screening or Day -1
• •Inability or difficulty swallowing pills
• •Unable or unwilling to communicate or cooperate with the Investigator